Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Current Assets (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Current Assets for 10 consecutive years, with $494.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets rose 45.38% to $494.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $494.8 million, a 45.38% increase, with the full-year FY2024 number at $374.2 million, up 21.39% from a year prior.
  • Current Assets was $494.8 million for Q3 2025 at Rhythm Pharmaceuticals, up from $360.7 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $494.8 million in Q3 2025 to a low of $235.8 million in Q1 2024.
  • A 5-year average of $338.2 million and a median of $340.3 million in 2024 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: soared 59.89% in 2021, then tumbled 38.5% in 2022.
  • Rhythm Pharmaceuticals' Current Assets stood at $308.4 million in 2021, then grew by 14.87% to $354.2 million in 2022, then fell by 12.98% to $308.3 million in 2023, then increased by 21.39% to $374.2 million in 2024, then surged by 32.23% to $494.8 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Current Assets are $494.8 million (Q3 2025), $360.7 million (Q2 2025), and $369.3 million (Q1 2025).